EPO906 Phase I 6-arm Trial to Optimize Administration Exploring Single Dose Bolus and Continuous Infusion Over 1 or 5 Days Every 3 or 4 Weeks in Patients With Pretreated Advanced Colon Cancer With Nutritional Support Treatment and Intensive Management of Diarrhea
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Patupilone (Primary)
- Indications Colon cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 09 Sep 2009 New trial record